What Is the Treatment of Enteropathy-Associated T-Cell Lymphoma?

Enteropathy-associated T-cell lymphoma (EATL) is a rare and aggressive intestinal T-cell lymphoma. First-line management follows a multimodal strategy, combining local surgical control with systemic treatment to achieve and sustain remission.

First-Line Approach — Partial Overview

When the patient can tolerate it, surgical resection of gross disease is performed as the initial step, followed by adjuvant chemotherapy. The complete regimen — including the specific chemotherapy protocol and its sequencing — is available in the full evidence-based protocol below.

Treatment Goals

The clinical target is complete response with no evidence of recurrence, confirmed through structured re-staging: CT imaging, small bowel contrast study, and upper gastrointestinal endoscopy with random biopsies performed at defined follow-up intervals.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1159/000205183

We suggest a multimodal approach that includes curative or debulking surgery to resect gross disease in all cases of EATLs, if tolerable, prior to chemotherapy.
Chemotherapy should be reserved as an adjuvant following resection, and long-term survival can be expected with its use.
Re-staging with computed tomography (CT) scan, small bowel contrast study and upper gastrointestinal (UGI) endoscopy with random biopsies at 6-month intervals have revealed no evidence of recurrence.
A repeat PET scan demonstrated an ongoing complete response.

View source ↗